Mozart Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Mozart Therapeutics's estimated annual revenue is currently $7.9M per year.
- Mozart Therapeutics's estimated revenue per employee is $155,000
- Mozart Therapeutics's total funding is $80M.
Employee Data
- Mozart Therapeutics has 51 Employees.
- Mozart Therapeutics grew their employee count by 6% last year.
Mozart Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | VP Non-Clinical Drug Development | Reveal Email/Phone |
5 | VP, Business Operations | Reveal Email/Phone |
6 | VP, Business Operations | Reveal Email/Phone |
7 | SVP, Research | Reveal Email/Phone |
8 | VP, Finance & Admin | Reveal Email/Phone |
9 | Sr Director Clinical Immunology | Reveal Email/Phone |
10 | Associate Director | Reveal Email/Phone |
Mozart Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $3.3M | 43 | 10% | $101M | N/A |
#4 | $5.7M | 37 | 12% | N/A | N/A |
#5 | $7M | 45 | 41% | N/A | N/A |
#6 | $1.7M | 22 | -8% | N/A | N/A |
#7 | $3.9M | 50 | 4% | $10.1M | N/A |
#8 | $1.9M | 12 | -73% | N/A | N/A |
#9 | $29.3M | 151 | -17% | $148M | N/A |
#10 | $2M | 13 | 86% | N/A | N/A |
What Is Mozart Therapeutics?
Founded on seminal work from leading scientists, Mozart is developing biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells. We are taking a new approach to establish immune balance to make a meaningful difference in the lives of patients.
keywords:N/A$80M
Total Funding
51
Number of Employees
$7.9M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.7M | 51 | -37% | N/A |
#2 | $8.6M | 51 | -12% | N/A |
#3 | $6.7M | 51 | 6% | N/A |
#4 | $6.9M | 51 | -2% | N/A |
#5 | $12.4M | 51 | -22% | $82M |